Racial differences in pathogenetic mechanisms, prevalence, and progression of benign prostatic hyperplasia - 16/08/11
Doi : 10.1016/j.urology.2006.08.1067
Gerald Hoke 1, a, William Baker †, 2, b, Carlton Barnswell 3, c, James Bennett d, Rodney Davis e, Terry Mason 4, f, Walter Rayford 5, g, h, ⁎ 
a Department of Surgery, Harlem Hospital Center, Columbia University, New York, New York
b Department of Urology, University of California, Davis, School of Medicine, Sacramento, California
c Department of Radiation Oncology, Long Island Jewish Medical Center, New York, New York
d Midtown Urology Surgical Center, Atlanta, Georgia
e Department of Urology, Tulane University Health Sciences Center, New Orleans, Louisiana
f Department of Urology, Mercy Hospital, Chicago, Illinois
g Southeast Urology Network, Memphis, Tennessee
h University of Tennessee, Memphis, Tennessee
Reprint requests: Walter Rayford, M.D., Ph.D., Southeast Urology Network, 995 South Yates, Suite 1, Memphis, TN 38119.Plan
© 2006
Elsevier Inc. Tous droits réservés.
Vol 68 - N° 5
P. 924-930 - novembre 2006 Retour au numéro
Article précédent
- Cyclooxygenase-2 inhibitors and other NSAIDs in urology: Current peril or future promise?
- Raj S. Pruthi, Erik Kouba, Culley C. Carson, Eric M. Wallen
- Comparing performance of Morbidity and Mortality Conference and National Surgical Quality Improvement Program for detection of complications after urologic surgery
- David C. Miller, Chris P. Filson, Lauren P. Wallner, James E. Montie, Darrell A. Campbell, John T. Wei
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?